Background: Human papillomavirus (HPV) is now known to be a necessary cause of
cervical cancer, and prophylactic HPV vaccines aimed at preventing genital warts …

Introduction: Recently, the evidence on efficacy and safety of prophylactic HPV vaccines
derived from randomized trials was published in the Cochrane database of Systematic …

We carried out a systematic review of HPV vaccine pre-and post-licensure trials to assess
the evidence of their effectiveness and safety. We find that HPV vaccine clinical trials design …

Persistent infection with one of the oncogenic human papillomavirus (HPV) types is a
necessity for the development of cervical cancer. By HPV vaccination, cervical cancer could …

Prophylactic human papillomavirus (HPV) vaccine represents a revolutionary step forward in
preventing HPV-related cancers, especially cervical carcinoma. Alongside appropriate …

Human papillomavirus (HPV) types cause approximately 70% of cervical cancer worldwide.
Two vaccines have been recently evaluated in randomized controlled trials: the bivalent …

Background We conducted a systematic review and meta-analysis to assess efficacy and
safety of prophylactic HPV vaccines against cervical cancer precursor events in women …

Human papillomavirus (HPV) is the most common sexually transmitted disease, worldwide.
Primary prevention thorough vaccination si able to reduce the burden of HPV-related …

Background Persistent infection with high‐risk human papillomaviruses (hrHPV) types is
causally linked with the development of cervical precancer and cancer. HPV types 16 and …

Vaccination against human papillomavirus (HPV) promises to dramatically decrease the
incidence of HPV-related diseases, including cervical cancer. Although this vaccine is …